Cenobamate
Brand names: Xcopri ยท Active ingredient: Cenobamate
In short: XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
What is Cenobamate used for?
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
Cenobamate dosage
Liver Function Tests
Prior to initiating XCOPRI, obtain serum transaminases (ALT and AST) and total bilirubin, if not recently available (i.e., within 3 months), to establish baseline liver function . For patients with baseline hepatic impairment, dosage modifications are recommended .
Monotherapy and Adjunctive Therapy
XCOPRI is administered orally once daily with or without food. The recommended dosage and titration, which should not be exceeded because of the potential for serious adverse reactions , is included in Table 1.
Initial Dosage
Week 1 and 2 | 12.5 mg once daily
Titration Regimen
Week 3 and 4 | 25 mg once daily
Week 5 and 6 | 50 mg once daily
Week 7 and 8 | 100 mg once daily
Week 9 and 10 | 150 mg once daily
Maintenance Dosage
Week 11 and thereafter | 200 mg once daily
Maximum Dosage
If needed based on clinical response and
tolerability, dose may be increased above 200 mg
by increments of 50 mg once daily every two
weeks to 400 mg. | 400 mg once daily
For patients with mild to moderate (Child-Pugh Class A to B) hepatic impairment, the maximum recommended dosage is 200 mg once daily . XCOPRI is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment .
XCOPRI can be taken whole or the tablets can be crushed. The crushed tablet can be mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube, as described below .
Administration of Crushed Tablets by Mouth as Oral Suspension
Crush the appropriate number of tablet(s) for the prescribed dose.
In a cup, combine the crushed tablet(s) and 25 mL of water.
Swirl to suspend the crushed tablet(s).
Drink the suspension immediately. Do not store the tablet-water mixture for later use.
To ensure no tablet residue is left in the container, rinse the container with 25 mL of water and drink.
Visually confirm that no particles are left in the container. If particles remain, repeat step 5.
Administration of Crushed Tablets via Nasogastric (NG) Tube
Crush the appropriate number of tablet(s) for the prescribed dose.
In an appropriate container, combine the crushed tablet(s) and 25 mL of water.
Swirl to suspend the crushed tablet(s).
Ensuring no particles are left in the container, instill the suspension with a syringe into the NG tube.
Refill the catheter-tip syringe again with 10 mL of water, swirl gently, and administer.
Visually confirm that no particles are left in the syringe. If particles remain, repeat step 5.
If XCOPRI is discontinued, the dosage should be gradually reduced over a period of at least 2 weeks, unless safety concerns require abrupt withdrawal .
How to take Cenobamate โ instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
DRESS/Multi-organ Hypersensitivity
Instruct patients and caregivers that a fever or rash associated with signs of other organ system involvement (e.g., lymphadenopathy, hepatic dysfunction) may be drug-related and should be reported to their healthcare provider immediately. XCOPRI should be discontinued immediately if a serious hypersensitivity reaction is suspected .
QT Shortening
Instruct patients to inform their healthcare provider of all of the medications, over-the-counter medications, and herbal supplements that they are taking. Instruct patients to notify their healthcare provider if they have any symptoms of shortening of the QT interval, including prolonged heart palpitations or a loss of consciousness .
Suicidal Behavior and Ideation
Counsel patients, their caregivers, and/or families that antiepileptic drugs, including XCOPRI, may increase the risk of suicidal thoughts and behavior, and advise patients to be alert for the emergence or worsening of symptoms of depression; unusual changes in mood or behavior; or suicidal thoughts, behavior, or thoughts about self-harm. โฆ
Warnings & precautions
Do not take this medicine if: XCOPRI is contraindicated in patients with:
Hypersensitivity to cenobamate or any of the inactive ingredients in XCOPRI
Familial Short QT syndrome
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking XCOPRI. DRESS has occurred, including one fatality, when XCOPRI was titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg once daily and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks . DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established .
In a placebo-controlled study of the QT interval, a higher percentage of subjects who took XCOPRI (31% at 200 mg and 66% at 500 mg) had a QT shortening of greater than 20 msec compared to placebo (6-17%). Reductions of the QTc interval below 300 msec were not observed . โฆ
Cenobamate side effects
The following serious adverse reactions are described in more detail in the Warnings and Precautions section of the labeling:
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity
QT Shortening
Suicidal Behavior and Ideation
Liver Injury
Neurological Adverse Reactions
Withdrawal of Antiepileptic Drugs
Because clinical trials are conducted under widely varying conditions and for varying durations, adverse reaction frequencies observed in the clinical trials of a drug cannot be directly compared with frequencies in the clinical trials of another drug and may not reflect the frequencies observed in practice.
In all controlled and uncontrolled trials performed in adult partial-onset seizure patients, XCOPRI was administered as adjunctive therapy to 1944 patients. Of these patients, 1575 were treated for at least 6 months, 710 for at least 12 months, 349 for at least 24 months, and 320 for at least 36 months. A total of 658 patients (442 patients treated with XCOPRI and 216 patients treated with placebo) constituted the safety population in the pooled analysis of placebo-controlled studies in patients with partial-onset seizures (Studies 1 and 2) . The adverse reactions presented in Table 4 are based on this safety population; the median length of treatment in these studies was 18 weeks. Of the patients in those studies, approximately 49% were male, 76% were Caucasian, and the mean age was 39 years. โฆ
Drug interactions
Table 5 summarizes the effect of XCOPRI on other drugs .
Drug or Substrate Type | Effect of XCOPRI on Drug or Substrate | Clinical Recommendation
Antiepileptic Drugs
lamotrigine | โ plasma concentrations | Because of a potential for reduced efficacy of these drugs, increase
the dosage of lamotrigine or carbamazepine, as needed, when used concomitantly with XCOPRI.
carbamazepine | โ plasma concentrations
phenytoin | โ plasma concentrations | Because of a potential 2-fold increase in phenytoin levels, gradually
decrease phenytoin dosage by up to 50% as XCOPRI is being titrated.
phenobarbital | โ plasma concentrations | Because of a potential for an increase in the risk of adverse
reactions from these drugs, consider a reduction in dosage of phenobarbital or clobazam, as clinically
appropriate, when used concomitantly with XCOPRI.
desmethylclobazam, the active metabolite of clobazam | โ plasma concentrations
CYP2B6 Substrates | โ plasma concentrations | Because of a potential for reduced efficacy of these drugs,
increase the dosage of CYP2B6 or CYP3A4 substrates, as needed, when used concomitantly with XCOPRI. โฆ
About this medicine
The chemical name of XCOPRI (cenobamate) is [(1R)-1-(2-Chlorophenyl)-2-(tetrazol-2-yl) ethyl] carbamate. Its molecular formula is C10H10ClN5O2 and its molecular weight is 267.67 g/mol. The chemical structure is:
Cenobamate is a white to off-white crystalline powder. It is slightly soluble in aqueous solutions (water 1.7 mg/mL) and has higher solubility in organic solvents like ethanol (209.4 mg/mL).
XCOPRI tablets are for oral administration and contain the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate and film coating agents specified below:
12.5 mg tablets: Not applicable, since 12.5 mg tablets are uncoated.
25 mg and 100 mg tablets: FD&C Blue# 2/indigo carmine aluminum lake, iron oxide red, iron oxide yellow, polyethylene glycol 3350, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.
50 mg tablets: iron oxide yellow, polyethylene glycol 3350, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide. โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 565c2126-57ae-4e29-b443-723bbe7e2072. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Oxcarbazepine Carbamazepine Ciclopirox